These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 28079792)

  • 61. Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401.
    ; Tanner M; Isola J; Wiklund T; Erikstein B; Kellokumpu-Lehtinen P; Malmström P; Wilking N; Nilsson J; Bergh J
    J Clin Oncol; 2006 Jun; 24(16):2428-36. PubMed ID: 16682728
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Adjusting breast cancer patient prognosis with non-HER2-gene patterns on chromosome 17.
    Kotoula V; Bobos M; Alexopoulou Z; Papadimitriou C; Papadopoulou K; Charalambous E; Tsolaki E; Xepapadakis G; Nicolaou I; Papaspirou I; Aravantinos G; Christodoulou C; Efstratiou I; Gogas H; Fountzilas G
    PLoS One; 2014; 9(8):e103707. PubMed ID: 25098819
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Simultaneous amplification of HER-2 (ERBB2) and topoisomerase IIalpha (TOP2A) genes--molecular basis for combination chemotherapy in cancer.
    Järvinen TA; Liu ET
    Curr Cancer Drug Targets; 2006 Nov; 6(7):579-602. PubMed ID: 17100565
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Validity of the proliferation markers Ki67, TOP2A, and RacGAP1 in molecular subgroups of breast cancer.
    Milde-Langosch K; Karn T; Müller V; Witzel I; Rody A; Schmidt M; Wirtz RM
    Breast Cancer Res Treat; 2013 Jan; 137(1):57-67. PubMed ID: 23135572
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Amplification of TOP2A and HER-2 genes in breast cancers occurring in patients harbouring BRCA1 germline mutations.
    Hagen AI; Bofin AM; Ytterhus B; Maehle LO; Kjellevold KH; Myhre HO; Møller P; Lønning PE
    Acta Oncol; 2007; 46(2):199-203. PubMed ID: 17453369
    [TBL] [Abstract][Full Text] [Related]  

  • 66. HER2, TOP2A, and TIMP-1 and responsiveness to adjuvant anthracycline-containing chemotherapy in high-risk breast cancer patients.
    Ejlertsen B; Jensen MB; Nielsen KV; Balslev E; Rasmussen BB; Willemoe GL; Hertel PB; Knoop AS; Mouridsen HT; Brünner N
    J Clin Oncol; 2010 Feb; 28(6):984-90. PubMed ID: 20038724
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Therapeutic strategies in male breast cancer: clinical implications of chromosome 17 gene alterations and molecular subtypes.
    Schildhaus HU; Schroeder L; Merkelbach-Bruse S; Binot E; Büttner R; Kuhn W; Rudlowski C
    Breast; 2013 Dec; 22(6):1066-71. PubMed ID: 24080492
    [TBL] [Abstract][Full Text] [Related]  

  • 68. The genomic profile of HER2-amplified breast cancers: the influence of ER status.
    Marchiò C; Natrajan R; Shiu KK; Lambros MB; Rodriguez-Pinilla SM; Tan DS; Lord CJ; Hungermann D; Fenwick K; Tamber N; Mackay A; Palacios J; Sapino A; Buerger H; Ashworth A; Reis-Filho JS
    J Pathol; 2008 Dec; 216(4):399-407. PubMed ID: 18810758
    [TBL] [Abstract][Full Text] [Related]  

  • 69. A phase II study of Epirubicin in oxaliplatin-resistant patients with metastatic colorectal cancer and TOP2A gene amplification.
    Tarpgaard LS; Qvortrup C; Nygård SB; Nielsen SL; Andersen DR; Jensen NF; Stenvang J; Detlefsen S; Brünner N; Pfeiffer P
    BMC Cancer; 2016 Feb; 16():91. PubMed ID: 26867764
    [TBL] [Abstract][Full Text] [Related]  

  • 70. HER-2, TOP2A and chromosome 17 alterations in breast cancer.
    Beser AR; Tuzlali S; Guzey D; Dolek Guler S; Hacihanefioglu S; Dalay N
    Pathol Oncol Res; 2007; 13(3):180-5. PubMed ID: 17922046
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Gene copy mapping of the ERBB2/TOP2A region in breast cancer.
    Jacobson KK; Morrison LE; Henderson BT; Blondin BA; Wilber KA; Legator MS; O'Hare A; Van Stedum SC; Proffitt JH; Seelig SA; Coon JS
    Genes Chromosomes Cancer; 2004 May; 40(1):19-31. PubMed ID: 15034864
    [TBL] [Abstract][Full Text] [Related]  

  • 72. [Correlation of TOP2A gene expression and survival of breast cancer patients].
    Meng H; Li WC; Wang LX; Li WB; Zhang L; Fan QX; Wang RL; Lu TY
    Zhonghua Zhong Liu Za Zhi; 2011 May; 33(5):363-6. PubMed ID: 21875466
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Predictive value of topoisomerase II alpha protein for clinicopathological characteristics and prognosis in early breast cancer.
    Wu Y; Han Y; Li Q; Zhang P; Yuan P; Luo Y; Fan Y; Chen S; Cai R; Li Q; Xu H; Wang Y; Ma F; Wang J; Xu B
    Breast Cancer Res Treat; 2022 Jun; 193(2):381-392. PubMed ID: 35297009
    [TBL] [Abstract][Full Text] [Related]  

  • 74. DNA topoisomerase IIalpha (TOP2A) inhibitors up-regulate fatty acid synthase gene expression in SK-Br3 breast cancer cells: in vitro evidence for a 'functional amplicon' involving FAS, Her-2/neu and TOP2A genes.
    Menendez JA; Vellon L; Lupu R
    Int J Mol Med; 2006 Dec; 18(6):1081-7. PubMed ID: 17089011
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Topoisomerase II alpha protein and responsiveness of breast cancer to adjuvant chemotherapy with CEF compared to CMF in the NCIC CTG randomized MA.5 adjuvant trial.
    O'Malley FP; Chia S; Tu D; Shepherd LE; Levine MN; Huntsman D; Bramwell VH; Andrulis IL; Pritchard KI
    Breast Cancer Res Treat; 2011 Jul; 128(2):401-9. PubMed ID: 21519837
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Metastatic breast cancer survival according to HER2 and Topo2a gene status.
    Todorović-Raković N; Nesković-Konstantinović Z; Nikolić-Vukosavljević D
    Dis Markers; 2009; 26(4):171-80. PubMed ID: 19729798
    [TBL] [Abstract][Full Text] [Related]  

  • 77. [Specific features of gene amplification on the long arm of chromosome 17 in different molecular genetic subtypes of breast cancer].
    Zavalishina LE; Danilova NV; Matsionis AE; Pavlenko IA
    Arkh Patol; 2014; 76(2):8-12. PubMed ID: 25051718
    [TBL] [Abstract][Full Text] [Related]  

  • 78. TIMP-1 in combination with HER2 and TOP2A for prediction of benefit from adjuvant anthracyclines in high-risk breast cancer patients.
    Hertel PB; Tu D; Ejlertsen B; Jensen MB; Balslev E; Jiang S; O'Malley FP; Pritchard KI; Shepherd LE; Bartels A; Brünner N; Nielsen TO
    Breast Cancer Res Treat; 2012 Feb; 132(1):225-34. PubMed ID: 22160637
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Underpinning the repurposing of anthracyclines towards colorectal cancer: assessment of topoisomerase II alpha gene copy number alterations in colorectal cancer.
    Nygård SB; Christensen IJ; Smith DH; Nielsen SL; Jensen NF; Nielsen HJ; Vainer B; Brünner N
    Scand J Gastroenterol; 2013 Dec; 48(12):1436-43. PubMed ID: 24138107
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Carbonic anhydrase IX is a predictive marker of doxorubicin resistance in early-stage breast cancer independent of HER2 and TOP2A amplification.
    Betof AS; Rabbani ZN; Hardee ME; Kim SJ; Broadwater G; Bentley RC; Snyder SA; Vujaskovic Z; Oosterwijk E; Harris LN; Horton JK; Dewhirst MW; Blackwell KL
    Br J Cancer; 2012 Feb; 106(5):916-22. PubMed ID: 22333602
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.